In short: SOLD — Q1 2026 "record" financials driven by metal-price tailwinds while AgEq output fell ~17% YoY and actual silver ounces dropped 11% post-Bolanitos; ~57% share dilution in twelve months leaves per-share net income below one cent; cost structure still elevated heading into H2; +220% locked in.
Guanajuato Silver reported what looked like a breakout quarter: record revenue, record EBITDA, first-ever quarterly profit. The catch is that almost all of it came from silver and gold prices hitting all-time highs — not from the company actually mining more metal. Silver-equivalent output fell 17% year-over-year and actual silver ounces dropped 11%, even after spending $30 million to acquire a new gold mine (Bolanitos). The operations went backwards; the metal prices bailed them out.
The share count is the other problem. A year ago GSVR had ~472 million shares. Today it is ~744 million — 57% more shares in twelve months from the acquisition, private placements and warrants converting. On those ~744 million shares that "record" $5.7 million quarterly profit is less than one cent per share. And management themselves flagged that the cost of production per ounce is still elevated heading into the second half of 2026 because the heavy capital-spending program is front-loaded, so margins remain thin at any price below today's highs.
Mart locked in a +220% gain and moved on. He is still bullish on silver and keeps other silver names in the portfolio, but he wants exposure to producers that stay profitable even if silver drops hard — and GSVR as currently structured cannot clear that bar. A great call option that delivered exactly what it should; not the right vehicle for the next leg.
Full passage: premium transcript (PDF).
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.